Skip to content

Can psychedelics improve well-being in autism?

Rachel Nuwer

Science December 20, 2024 DOI: 10.1126/science.adv4102 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Population Autistic adults with social anxiety
Topics Psychedelic-assisted therapy
Keywords Autism treatment Mental health research Social anxiety Clinical trials
Citations 1
Key findings One trial found significant reduction in social anxiety with psychedelic therapy, while another found no significant difference between treatment and placebo groups.

Abstract

A brace of new studies probes benefits and risks for an understudied group.

Comparable studies

Other randomized controlled trials on psychedelic-assisted therapy, most cited first.

Study Year Design Participants
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Healthy adults, mostly hallucinogen-naïve 2011 Randomized controlled trial n = 18
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases Patients with anxiety associated with life-threatening diseases 2014 Randomized controlled trial n = 12
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Patients with chronic post-traumatic stress disorder refractory to both psychotherapy... 2010 Randomized controlled trial n = 20
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder Adults aged 25–65 with DSM-IV alcohol dependence and at least 4 heavy drinking days in... 2022 Randomized controlled trial n = 95
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Military veterans and first responders aged 18 or older with chronic PTSD lasting 6... 2018 Randomized, double-blind, dose-response, phase 2 clinical trial n = 26

Citations in the library

Explore topics